• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Delcath Systems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    5/29/24 4:06:31 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care
    Get the next $DCTH alert in real time by email
    8-K
    NASDAQ false 0000872912 0000872912 2024-05-23 2024-05-23

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 23, 2024

     

     

    Delcath Systems, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-16133   06-1245881
    (State or other jurisdiction
    of incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    566 Queensbury Avenue

    Queensbury, New York

      12804
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (212) 489-2100

     

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities pursuant to Section 12 (b) of the Act:

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

     

    Trading
    Symbol(s)

     

    Name of Each Exchange

    on Which Registered

    Common Stock, $0.01 par value   DCTH   The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 3.01

    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    The information in Item 5.07 of this Current Report on Form 8-K under the heading “Appointment of Director/Nasdaq Listing Rule 5605(c)(2)” as it relates to the audit committee (“Audit Committee”) of the board of directors (the “Board”) of Delcath Systems, Inc. (the “Company”) is hereby incorporated by reference in this Item 3.01.

     

    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Omnibus Equity Incentive Plan

    At the 2024 annual meeting of stockholders held on May 23, 2024 (the “Annual Meeting”), the stockholders of the Company approved an amendment to the Company’s 2020 Omnibus Equity Incentive Plan (the “2020 EIP”) to increase by 2,000,000 the number of shares of the Company’s common stock, $0.01 par value (the “Common Stock”) available thereunder.

    A more detailed summary of the material features of the 2020 EIP, as amended, including the terms of stock option grants thereunder, is set forth in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 12, 2024 (the “2024 Proxy Statement”). That summary and the foregoing description are qualified in their entirety by reference to the text of the 2020 EIP, as amended, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Appointment of Director/Nasdaq Listing Rule 5605(c)(2)

    Following the voting on Proposal 1 (as listed below in Item 5.07) at the Annual Meeting on May 23, 2024, Roger Stoll’s previously announced retirement from the Board took effect. On March 24, 2024, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) of the retirement of Roger Stoll from the Board and the Audit Committee. With Dr. Stoll’s retirement the Audit Committee currently is comprised of only two qualified Directors. Pursuant to Nasdaq Listing Rule 5605(c)(2), the Audit Committee must be comprised of at least three qualified Directors. On May 29, 2024, the Company received notice from Nasdaq confirming that the Company was no longer in compliance with such Nasdaq Listing Rule. The Company intends to fill the vacancy on the Audit Committee as expeditiously as possible. The Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) until the earlier of the Company’s next annual meeting or May 23, 2025. The Company will regain compliance with the audit committee composition requirements of Nasdaq Listing Rule 5605(c)(2)(A) by the end of the cure period.

    Additionally, in connection with Roger Stoll’s retirement from the Company’s Board, on May 23, 2024, the Company appointed Bridget Martell, M.A. M.D., as a Class III Director on the Company’s Board, commencing on May 23, 2024 and continuing until her term on the Board expires at the Company’s 2027 Annual Meeting.

    At this time, Dr. Martell has not been named to any committees of the Board. There are no arrangements or understandings between Dr. Martell and any other persons pursuant to which she was elected as a director, and there are no transactions between Dr. Martell and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

    A copy of the Company’s press release related to Dr. Martell’s appointment to the Board is attached as Exhibit 99.1 to this Current Report on Form 8-K.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders

    At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more detail in the 2024 Proxy Statement. Of the 27,433,579 shares of the Common Stock outstanding and convertible preferred stock eligible to vote as of the record date, 18,089,113 shares, or approximately 65.94%, were present or represented by proxy at the Annual Meeting.


    The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each such matter.

    Proposal 1. Stockholders elected the following nominee to serve as a Class III director on the Board until the Company’s 2027 Annual Meeting or until his successor has been duly elected and qualified. The voting results for such nominee was as follows:

     

    Director Name    Votes For      Votes Withheld      Broker Non-
    Votes
     

    Steven Salamon

         13,411,468        122,297        4,555,348  

    Proposal 2. Stockholders approved the amendment to the 2020 EIP to increase by 2,000,000 the number of shares of Common Stock available under thereunder. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-
    Votes
    13,022,078   498,186   13,501   4,555,348

    Proposal 3. Stockholders ratified the selection by the Audit Committee of the Board of Marcum, LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2024. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-
    Votes
    17,870,451   199,555   19,107   N/A

    Proposal 4. Stockholders approved a non-binding advisory vote on the compensation of the Company’s named executive officers. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-
    Votes
    13,070,270   432,115   31,380   4,555,348

     

    Item 9.01

    Financial Statements and Exhibits

    (d) Exhibits

     

    Exhibit
    No.

      

    Description

    10.1    2020 Omnibus Equity Incentive Plan, as amended
    99.1    Press Release of Delcath Systems, Inc. dated May 28, 2024
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 29, 2024     DELCATH SYSTEMS, INC.
        By:  

    /s/ Gerard Michel

        Name:   Gerard Michel
        Title:   Chief Executive Officer
    Get the next $DCTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DCTH

    DatePrice TargetRatingAnalyst
    6/28/2024$18.00Buy
    Craig Hallum
    5/14/2024$25.00Overweight
    Stephens
    7/26/2022$17.00Buy
    Canaccord Genuity
    12/10/2021$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $DCTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

    Publication Highlights Promise of Combined Percutaneous Hepatic Perfusion and Immunotherapy in Metastatic Uveal Melanoma Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Principal Investigator Professor Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology. The publication, titled "Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre

    3/3/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

    Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $19.0 million and $78.8 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.7 million and $6.4 million, respectively Gro

    2/26/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

    Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1747469&tp_key=15ec7bd15c A replay of the w

    2/12/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    10/2/24 4:43:10 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

    5/23/24 10:32:08 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    1/23/24 4:36:46 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    SEC Filings

    View All

    SEC Form DEFA14A filed by Delcath Systems Inc.

    DEFA14A - DELCATH SYSTEMS, INC. (0000872912) (Filer)

    4/2/26 8:55:31 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Delcath Systems Inc.

    DEF 14A - DELCATH SYSTEMS, INC. (0000872912) (Filer)

    4/2/26 8:52:52 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Delcath Systems Inc.

    8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

    3/3/26 4:48:16 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Pennell Sandra bought $50,018 worth of shares (5,533 units at $9.04), increasing direct ownership by 8% to 77,018 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/6/26 4:22:21 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Michel Gerard J bought $100,309 worth of shares (11,200 units at $8.96), increasing direct ownership by 3% to 342,034 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/3/26 4:15:22 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Director Sylvester John Richard bought $38,992 worth of shares (4,386 units at $8.89), increasing direct ownership by 42% to 14,936 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    11/25/25 4:15:07 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Pennell Sandra bought $50,018 worth of shares (5,533 units at $9.04), increasing direct ownership by 8% to 77,018 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/6/26 4:22:21 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Michel Gerard J bought $100,309 worth of shares (11,200 units at $8.96), increasing direct ownership by 3% to 342,034 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/3/26 4:15:22 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by GM INTERVENTIONAL ONCOLOGY Muir Kevin

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    2/18/26 9:30:13 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Delcath with a new price target

    Craig Hallum initiated coverage of Delcath with a rating of Buy and set a new price target of $18.00

    6/28/24 8:18:39 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Stephens initiated coverage on Delcath with a new price target

    Stephens initiated coverage of Delcath with a rating of Overweight and set a new price target of $25.00

    5/14/24 7:58:22 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity resumed coverage on Delcath with a new price target

    Canaccord Genuity resumed coverage of Delcath with a rating of Buy and set a new price target of $17.00

    7/26/22 9:10:21 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Financials

    Live finance-specific insights

    View All

    Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

    Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $19.0 million and $78.8 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.7 million and $6.4 million, respectively Gro

    2/26/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

    Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1747469&tp_key=15ec7bd15c A replay of the w

    2/12/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

    Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Total revenue of $20.6 million, compared with $11.2 million in the third quarter of 2024 HEPZATO KIT™ revenue of $19.3 million, compared to $10.0 million in the third quarter of 2024 CHEMOSAT® revenue of $1.3 million, compared to $1.2 million in the third quarter of 2024 Gross margins of 87%, compared to 85% in the third quarte

    11/4/25 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/15/24 10:33:51 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/14/24 9:46:56 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Delcath Systems Inc.

    SC 13G/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/14/24 7:02:01 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    Leadership Updates

    Live Leadership Updates

    View All

    Beta Bionics Announces Board Appointment of Gerard Michel

    IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

    3/27/25 4:45:06 PM ET
    $BBNX
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

    Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

    5/28/24 9:30:00 AM ET
    $ACHV
    $ALGS
    $DCTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medical/Dental Instruments

    Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

    NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO). Martha S. Rook, Ph.D., is an experienced industry leader who brings more than 25 years of academic and industry experience in molecular biology, diagnostics development, biologics process development and biologics manufacturing. She joins Delcath from insitro where she

    3/18/24 5:20:00 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care